Figure 5.

Forest plot of rate ratios between monthly fold changes in anti-SARS-CoV-2 RBD IgG concentration in SOT recipients with intervals of more or less than six months between their last two BNT162b2-containing vaccine doses. Results from linear mixed models showing rate ratios between monthly fold changes in anti-SARS-CoV-2 RBD IgG concentration in SOT recipients with intervals of more or less than six months between their last two BNT162b2 vaccine doses stratified by SARS-CoV-2 infection status. Adjustments in models containing all SOT recipients included sex, age, transplant type, infection status (infection-naïve, previous infection, and infected during follow-up), and monoclonal antibody treatment within 6 months prior to the baseline sample. Adjustments in models including SOT recipients not infected between baseline and follow-up included sex, age, transplant type, infection status (infection-naïve and previous infection), and monoclonal antibody treatment within 6 months prior to baseline sample. Adjustments in models including only infection-naïve SOT recipients included sex, age, and transplant type.